News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alder Biopharmaceuticals Inc. Release: Data From Proof-Of-Concept Clinical Trial Of ALD403, A Monoclonal Antibody Against CGRP For The Prevention Of Migraine, To Be Presented At 56th Annual Scientific Meeting Of The American Headache Society



6/26/2014 7:22:03 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BOTHELL, Wash., June 26, 2014 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. ("Alder") (Nasdaq:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, autoimmune and inflammatory diseases, today announced Peter J. Goadsby, M.D., Ph.D., director, NIHR-Wellcome Trust Clinical Research Facility, King's College London and director, Headache Center, Department of Neurology, University of California, San Francisco, and David W. Dodick, M.D., professor of neurology at the Mayo Clinic, will present results from a randomized, double-blind, placebo-controlled, proof-of-concept clinical trial of ALD403 for the prevention of frequent episodic migraine at the 56th Annual Scientific Meeting of the American Headache Society at the Hyatt Regency Century Plaza in Los Angeles, California.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   
Migraine

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES